|Bid||2.3000 x 1800|
|Ask||2.4200 x 4000|
|Day's Range||2.2600 - 2.4250|
|52 Week Range||1.8000 - 6.5000|
|Beta (3Y Monthly)||2.75|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 23, 2019 - May 24, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||30.00|
If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. But...
Sorrento Therapeutics (SRNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sorrento Therapeutics, Inc. (SRNE) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
SAN DIEGO, July 02, 2019 -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a clinical stage, antibody-centric biopharmaceutical company developing new therapies to.
Sorrento Therapeutics news for Friday concerning a new equity offering has SRNE stock falling hard.Source: Shutterstock Sorrento Therapeutics (NASDAQ:SRNE) notes that it will be making a public offering of its common stock. It will also be offering Series A, Series B and Series C warrants to purchase shares of its common stock. The company will be selling these shares an accompany warrants for $3.00 each.The Sorrento Therapeutics news release notes that the company is planning to use funds from this public offering for a variety of purposes. This includes "continued clinical development of its RTX, CEA CAR-T and CD38 CAR-T programs and general research and development, working capital and general corporate purposes."InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe public offering from Sorrento Therapeutics includes 8,333,334 shares of SRNE stock and Series A, Series B and Series C warrants to purchase an aggregate of 8,333,334 shares of SRNE stock. Underwriters of the offer will also have the option of purchasing an additional 15% of shares and or warrants in the public offering.The Sorrento Therapeutics news also includes the restrictions on the warrants. This includes the Series A warrants being exercisable six months after purchase for a price of $3.75 and expire after 10 years. * The 7 Top Small-Cap Stocks Of 2019 As for the Class B warrants, they are exercisable at the time of issuance for $3.00 and expire nine months after that date. The Class C warrants are exercisable after purchase for $3.75 and expire after 10 years. This warrants also require that the corresponding Class B warrant be exercised.The public offering is expected to last through July 2.SRNE stock was down 18% as of noon Friday. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The 7 Top Small-Cap Stocks Of 2019 * Critical Levels to Watch in 7 Marijuana Stocks * 5 Smaller Cloud Stocks That Have Plenty of Potential As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Sorrento Therapeutics News: SRNE Stock Tanks on Equity Offering appeared first on InvestorPlace.
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a clinical stage, antibody-centric biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases, today announced the pricing of its public offering of 8,333,334 shares of its common stock, Series A warrants to purchase up to an aggregate of 8,333,334 shares of its common stock, Series B warrants to purchase up to an aggregate of 8,333,334 shares of its common stock and Series C warrants to purchase up to an aggregate of 8,333,334 shares of its common stock, at a price to the public of $3.00 per share and accompanying Series A, Series B and Series C warrant. The Series A warrants will be exercisable commencing six months from the date of issuance, will expire on the 10-year anniversary of the date of issuance and will have an exercise price of $3.75 per share, subject to certain adjustments.
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a clinical stage, antibody-centric biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and Series A, Series B and Series C warrants to purchase shares of its common stock in an underwritten public offering. Sorrento also expects to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the shares of common stock and/or warrant combinations, which consist of Series A, Series B and Series C warrants, offered in the public offering on the same terms and conditions.
Sorrento Therapeutics Inc (NASDAQ: SRNE ) announced Wednesday that the Phase 1b study of its drug resinferatoxin is in progress and has generated positive data. The RTX drug has the potential to be on ...
“CD38 Therapeutics” Business Unit formed to focus on development of CD38-directed immunotherapies for potential out-licensing, collaboration and/or other strategic.
Forty five patients were treated with escalating doses of RTX in the Phase 1b trial to date. Thirty seven patients received RTX and eight patients received saline (pooled as placebo group). Most adverse events associated with RTX administration were expected and included pain, hypertension and tachycardia.
SAN DIEGO, June 14, 2019 -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announces today that senior management will be presenting in the upcoming JMP Life Sciences.
Sorrento Therapeutics, Inc. (Sorrento, Nasdaq: SRNE) today announced that it is exploring the possibility of an initial public offering of its majority-owned subsidiary, Scilex Holding Company. No decisions have been taken at this point on the structure or timing of any initial public offering, and no assurance can be given that an initial public offering will be pursued or completed. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.
Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced that review of early results from an on-going “declawed cat pain trial” (run by its Ark Animal Health division) prompted management to assign a high priority to exploring the use of resiniferatoxin as a local nerve block injection for the control of neuropathic post-amputation residual limb pain in humans. The population of “aging amputee cats” living with the sequalae of surgeries performed years ago is quite large making it a valuable “model” when looking at residual limb pain which affects about 30% of the 1.6 million American amputees, or phantom limb pain which affects up to 70% of those human patients1.
Scilex Holding Company (Scilex), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (SRNE), announces the completion of post-merger integration. Following the merger with Semnur Pharmaceuticals, Inc. in March 2019, and the contribution of Scilex Pharmaceuticals Inc. equity to Scilex Holding Company, Scilex rapidly proceeded to implement key changes necessary to ensure the long-term success of the newly formed company. Gross sales in the past three months have shown strong and sustained month-over-month growth, increasing from approximately $1 million in March, to $2.4 million in April and $3.3 million in May, respectively.
SAN DIEGO, June 04, 2019 -- Sorrento Therapeutics, Inc. (Sorrento, Nasdaq: SRNE) announces that it has formed a Chinese joint venture, Shenzhen Yunma Biotechnology Co., Ltd..
SAN DIEGO, May 21, 2019 -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will be participating in the upcoming FB.
HENDERSON, NV / ACCESSWIRE / April 18, 2019 / Cannabis stocks were a sea of red on Monday, weighed down by Aphria Inc. after it swung to a wide loss in the third quarter that outweighed a surge in revenue. ...
Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced that its Neuro-Therapeutics unit is pursuing clinical development of resiniferatoxin (RTX) for multiple life-threatening cardiovascular disorders, including IND enabling toxicology and proof-of-principle animal studies. RTX has potential clinical benefits derived from its ability to modulate neurogenic inflammation and afferent nerve signaling commonly associated with chronic degenerative conditions.